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I N T R O D U C T I O N
Urea clearance (Kt/V) is expressed as a fraction of the body water volume. In the Haemodialysis it is a measure of the dose of a single dialysis session [1] . In peritoneal dialysis (PD), it includes the effect of renal function and is a measure of clearance over a defined period, normally a week. Kt/V is one of the principal quality indicators for dialysis. Current guidelines for dialysis all recommend ensuring that Kt/V exceeds a specified minimum level. The guidelines do not explicitly consider the age or frailty of the dialysis patient in setting the minimum Kt/V [2] [3] [4] [5] .
For practical purposes, in Europe, a person may be considered elderly at the age of 65 years. This originates from 'Gesetz betreffend der Invaliditäts-und Altersversversicherung', a law enacted in 1883 by Otto von Bismarck, regulating financial support in case of incapacity and in old age, defined as beginning at the age of 65 years. Since then, in many developed countries, the age of retirement has been defined more flexibly, taking biological functional capacity into account. In other parts of the world, particularly in underdeveloped and developing countries, the age of 60 years is considered the limit between adulthood and old age. The World Health Organization defines elderly as age !60 years, which would include the majority of dialysis patients. Current guidelines for treatment of the elderly disagree with the definition of 'elderly' or lack a definition entirely [6] . Dialysis patients are usually considered as elderly when they are >75 years old [7, 8] . For the purpose of searching and analysing the literature, we used !65 years as the definition of elderly. This value was selected after much discussion, as a higher age cut-off would exclude much of the literature and include a greater proportion of atypical 'super-survivors' with low multimorbidity.
Frailty in dialysis patients has been defined as a combination of exhaustion, weakness, low physical activity and weight loss [9] . Frailty has multiple causes in addition to advancing age.
A joint initiative of the European Renal Association European Dialysis Transplant Association (ERA-EDTA) and the European Union of Geriatric Medicine Societies (EUGMS) prioritized the development of guidance on interdisciplinary referral of older patients with chronic kidney disease (CKD) Stages 3b-5 and listed 'the usefulness of Kt/V' in this special population as a topic of interest [10] .
Effect of increasing dialysis dose
Variations in dialysis dose are likely to be accompanied by advantages and disadvantages (Table 1 ) and the optimal dose of dialysis will account for both. It is conceivable that the priorities for elderly patients will differ from those of younger patients and the optimal dose will also differ.
Haemodialysis (HD)
The current European guidelines recommend a minimum of three dialysis sessions per week totalling at least 12 h, with a Kt/ V of at least 1.2 each session. This can be reduced if there is significant renal function. The recommendation was based on the findings of a reanalysis of the National Co-operative Dialysis Study (NCDS) published in 1982 [16] . Numerous observational studies have shown an association between Kt/V and outcome.
PD
Current guidelines recommend that the total of dialysis and renal Kt/V should be at least 1.7 per week. This was informed by the Adequacy of PD in Mexico (ADEMEX) study [17] , one of the very few randomized controlled trials (RCTs) designed to investigate the effect of different Kt/Vs (it showed no benefit in increasing Kt/V to >1.7/week). Numerous observational studies have suggested worse outcome is associated with a lower dose.
Increasing age is accompanied by physiological and pathological changes that could influence the generation of uraemic toxins and the ease with which they may be removed by dialysis (Table 2) . These changes may influence the relationship between Kt/V and outcome and therefore the optimal dose of dialysis.
Metabolic rate and energy expenditure fall as a function of age in healthy individuals [18, 22] . On average, a person 80 years of age will have a reduction in energy expenditure 20% lower than a 40-year old [18] . In theory, the rate of generation of uraemic toxins will be reduced by a similar amount. Dialysis • Improved volume management (frequent short dialysis) [11] • Increased overall survival (frequent short dialysis) [12] • Increased frequency of surgical/access interventions (frequent HD) [13] • Increased infections (frequent HD) [14] • Increased time having treatment • Reduced survival (frequent nocturnal dialysis) [15] Kt/V in elderly dialysis patients patients !65 years of age have $25% lower salt and protein intake compared with younger patients [19] . Therefore, compared with younger patients, the elderly would tend to have lower serum concentrations of these toxins if clearance remains the same. In these circumstances, dialysis dose could be reduced in elderly patients without allowing toxin levels to rise above those considered acceptable in younger patients. Elderly dialysis patients tend to have lower interdialytic fluid weight gain [21] and better compliance with sodium restrictions [23] . This tends to reduce the requirement for ultrafiltration, allowing either a slower ultrafiltration rate at the same dialysis time or a shorter dialysis with the same ultrafiltration rate compared with younger patients.
Muscle contains relatively more water, especially intracellular water, compared with other tissues. The reduction in muscle mass, which accompanies increasing age [24] , results in relatively lower total body water volume [25] . In general, the proportion of body water that is intracellular is lower in the elderly compared with younger patients. Elderly persons with immobility have been shown to have increased total body water compared with the mobile elderly [26] . This is likely to be due to water retention. Body water volume, as V, has a major influence on Kt/V, regardless of the concentration of uraemic toxins. When Kt/V is calculated using online clearance, V calculated using anthropometric data is often used. This is likely to be highly inaccurate in the elderly. V calculated using bioimpedance may provide a better estimate [27] . During intermittent dialysis, a rapid decrease in solute concentrations in plasma causes a disequilibrium or difference in osmotic pressure between body compartments, which could cause headache and other intradialytic symptoms. The magnitude of this disequilibrium will depend on the initial solute concentration and the Kt/ V ratio.
Elderly patients are more likely to have multimorbidity, including heart failure, arterial disease and autonomic dysfunction. These conditions reduce the patients' tolerance to HD ultrafiltration and increase the risk of hypotension during HD.
Hypotension usually causes symptoms and may result in early termination of dialysis. Repeated episodes may result in damage to the heart and brain [28] .
Older age is a risk factor for receiving a lower dialysis dose [29] . This may be because age-associated cardiovascular disease predisposes the patient to intradialytic hypotension, resulting in shortened or interrupted dialysis. Similarly, cardiovascular disease may contribute to poor vascular access, resulting in inadequate extracorporeal blood flow or interrupted dialysis ( Figure 1 ).
Multimorbidity, which is likely in elderly dialysis patients, could render the patient more susceptible or sensitive to the effects of uraemia. In contrast, survival and quality of life could be overwhelmingly limited by multimorbidity so uraemia and dialysis dose could be irrelevant.
The frailty of advanced age may be associated with cognitive dysfunction, immobility, motor dysfunction and incontinence. These will cause logistical and practical problems in providing adequate dialysis. The ability of the patient to become involved in dialytic care will be reduced. The patient could be distressed by dialysis, especially when dialysis sessions are longer, more frequent or hospital based.
P A L L I A T I V E D I A L Y S I S
Conservative management of end-stage renal failure without dialysis is increasingly accepted as an appropriate option for selected elderly patients, especially those with severe multimorbidity and frailty. It makes sense for the options for such patients to include an intermediate 'palliative dialysis' aimed at controlling uraemic symptoms but not necessarily avoiding long-term complications [30] . Such 'palliative dialysis' would be designed to have lower treatment burden than standard dialysis and may include twice-weekly or shorter sessions with lower Kt/V. All available means for controlling symptoms and maximizing physical and cognitive function would be considered to augment the effect of dialysis. These might include non-dialysis treatments such as drugs, dietary restrictions, maximizing residual renal function and physical and psychological therapy in combination with dialysis. The risk that palliative options might be used as a means of ageist rationing of dialysis may be reduced by a rigorous patient-centred approach [31] .
Twice-weekly dialysis
In observational studies, patients dialyzing twice weekly have better preservation of renal function [32] and improved survival [33] compared with those dialyzing with conventional thriceweekly dialysis regimes. These associations are likely to be due to patient selection; patients with more renal function are more likely to be selected for and remain on twice-weekly dialysis. Elderly patients may have lower rates of generation of uraemic toxins and lower fluid weight gains and thus may be better able to tolerate twice-weekly HD. An RCT is needed to compare outcomes of twice-weekly versus thrice-weekly dialysis in selected patients.
Incremental dialysis
Renal function is known to contribute significantly to clearance during the first few years of dialysis [34] . Residual renal function is known to have even greater effect on outcome than dialysis dose for both HD [35] and PD [36] . The effect of renal function on fluid balance, reducing the need for ultrafiltration, may be particularly important.
With incremental dialysis, residual renal function is taken into account in the prescription. Patients with significant renal function are prescribed a shorter, less frequent and/or less intense dialysis. The dialysis dose may be increased later to compensate for declining renal function. The combined effect of the renal function plus the reduced-dose dialysis should be equivalent to or exceed what constitutes a full dose of dialysis in an anuric patient.
Renal function has different effects on patients compared with dialysis, so it is not sufficient to simply add a function of dialysis dose (e.g. Kt/V) to a measure of renal function. Compared with standard full-dose dialysis, patients treated by incremental dialysis require more careful monitoring of fluid status, nutrition and the levels of key uraemic toxins to ensure that they are getting sufficient dialysis as renal function declines [37] .
Multiple observational studies have confirmed that patients with significant renal function has improved survival compared with anuric patients [36] , even if the dialysis dose is reduced as part of an incremental dialysis programme [38] .
A recent large observational study found that there was no difference in survival rates between patients treated by incremental versus standard HD. However, in patients with urine volume <600 mL/day or renal urea clearance <3 mL/min/ 1.73 m 2 , incremental dialysis was associated with significantly reduced survival [39] .
Incremental dialysis has a lower burden of treatment. There appears to be no adverse clinical effects during the first few years of dialysis [40] and when there is significant renal function. The advantages of incremental dialysis might be particularly important for elderly patients with short life expectancy, where transplantation is not an option [41] . Incremental dialysis is typically employed in PD. There is increasing interest in incremental HD, particularly as a way to allow once-or twice-weekly dialysis. An RCT is required to compare the safety and efficacy of incremental dialysis with standard full-dose HD in incident dialysis patients.
Intensive dialysis
It has been hypothesized that intensive dialysis will result in better clearance of uraemic toxins and that this will result in reduced symptoms and improved survival. Observational studies have found associations between longer, more frequent or more intensive dialysis and improved outcome, particularly for home treatments [42] . If dialysis time is also increased, fluid balance is easier to achieve, with lower ultrafiltration rates.
The HEMO Study did not show improved survival in patients randomized to receive an increased dose of dialysis. Pruritus was reduced in the high-dose group, but there were no other significant benefits. In the Frequent Hemodialysis Network trials, patients randomized to frequent nocturnal dialysis had reduced survival compared with standard home dialysis. Frequent short dialysis was associated with increased survival but more numerous infections and access interventions.
A recent pro-con debate on dialysis regimens in the elderly concluded that while there was no strong evidence to support intensive dialysis in general, a limited trial of intensive dialysis may be justified in more problematic patients [43] .
K t / V I S U S E F U L I N T H E E L D E R L Y : T H E P R O A R G U M E N T
Malnutrition is prevalent in elderly dialysis patients [24] and has been associated with an increased risk of death [44, 45] . Anorexia is a known symptom of uraemia and is likely to contribute to malnutrition. It has been hypothesized that low Kt/V could be a risk factor for malnutrition in dialysis patients [46, 47] . While there are likely to be multiple other potential causes of malnutrition in elderly dialysis patients [48] [49] [50] , low Kt/V is an easily identifiable and potentially modifiable risk factor [51] .
Multiple observational studies have shown that low Kt/V is associated with mortality [40, 52] , especially in anuric patients [38] . This has been shown in a dialysis population with a relatively high percentage of elderly patients [53] . Low Kt/V is considered a modifiable risk factor for mortality in dialysis patients [54] . There is no evidence that elderly patients are any less susceptible to any adverse effects of low Kt/V.
The HEMO and ADEMEX RCTs have shown no benefit of increasing Kt/V above the standard dose. This does not mean that reducing Kt/V below the standard dose is safe or that Kt/V is not a valuable quality measure to detect inadequate dialysis. There is no RCT evidence showing that reducing Kt/V in anuric patients is safe.
One of the aims of medical treatment in the elderly is to improve quality of life. In a prespecified secondary analysis of the HEMO Study, a significantly slower decline in physical health, as expressed by the physical component summary, and a slower worsening in bodily pain were observed in patients assigned to an equilibrated Kt/V of 1.45 compared with a lower dialysis dose (1.05) [55] . Although the mean age of patients in the HEMO Study was 57.6 years, the study included a significant number of patients !65 years of age. Other studies have shown that older people who are adequately dialyzed (Kt/V > 1.2) have a relatively good health-related quality of life (HRQOL) similar to that of the general population of the same age and gender [56] and experience a similar decline in HRQOL compared with younger patients undergoing HD [57] .
Kt/V can be calculated for both renal function and dialysis and combined as a single measure. Incremental dialysis, minimizing the negative impact on the patient by minimizing treatment time and/ or frequency yet maintaining overall adequacy, guided by measurements of renal and dialysis Kt/V, has been shown to have superior outcomes [39] . Incremental dialysis, with its reduced dose, might potentially increase the risk of developing uraemic symptoms and fluid overload, especially when residual renal function fails completely [39] . As a consequence, additional evidence is required to inform daily clinical practice. If it is implemented, incremental dialysis would require careful control and monitoring, including serial measurements of renal function and clearance by Kt/V.
One of the aims of medical treatment in the elderly is to reduce symptoms. Unfortunately, many of the potentially reversible symptoms of uraemia are difficult to distinguish from the unavoidable effects of ageing and age-associated multimorbidity. Pruritus is one of the few symptoms that is relatively specific for uraemia. Higher Kt/V has been associated with reduced pruritus in the majority [58] [59] [60] but not all [61] of the observational studies where this was reported. This association was shown in Dialysis Outcomes and Practice Patterns Study (DOPPS) 1 [62] but failed to reach significance in DOPPS II.
Although urea is not particularly toxic, it has several characteristics that make it suitable as a tracer to quantify dialysis. These include free movement across the erythrocyte and tissue cell membranes [63] , stability in blood samples, relative lack of non-renal, non-dialysis clearance and low cost of measurement. As Kt/V is calculated from the ratios of urea concentrations in pre-and post-HD blood, urine or dialysis fluid samples, calibration errors affecting all samples equally will not result in an error in Kt/V. Urea-based Kt/V is the best-studied marker of dialysis adequacy. The use of Kt/V is supported by a wellknown and studied urea kinetic model (UKM). The UKM can be applied to all types of dialysis. Computer applications to run the UKM are widely available and run on most computing devices. The UKM can be used to calculate protein nitrogen appearance, a marker of dietary protein catabolism. The UKM can predict Kt/V for any dialysis prescription and hence can be used to ensure adequate dialysis and detect unaccounted for inefficiency in the dialysis process. Modern dialysis machines can now measure Kt/V continuously and inexpensively without blood samples using online measurements of conductivity or ultraviolet absorbance. There is much more published evidence linking Kt/ V to outcome than any other marker of dialysis adequacy.
Although other measures of dialysis adequacy using arguably more realistic uraemic toxins have been proposed [64] [65] [66] , none are as well-validated as Kt/V. Many of these alternative methods increase complexity and cost.
K t / V I S N O T U S E F U L I N T H E E L D E R L Y : T H E C O N A R G U M E N T
The use of the urea-based Kt/V has been questioned recently [67] . The handling of urea by dialysis and the kidneys is not typical of uraemic toxins. Compared with other toxins, urea diffuses more rapidly, is reabsorbed in the renal tubules and, due to specific channels, transfers much more readily across cell membranes. Therefore urea is more easily cleared by dialysis and less easily cleared by the kidneys compared with other toxins. Protein-bound toxins are barely cleared by dialysis. Nondialysis clearance and generation rates are highly variable between patients and have relatively greater influence on the levels of these uraemi toxins than dialysis clearance. Kt/V does not predict levels of uraemic toxins in dialysis patients [68, 69] .
The hypothesis that increasing Kt/V improves nutrition is not supported by the evidence. Nutritional markers were not different between standard and high-dose groups in both the ADEMEX and HEMO studies [70] . In the Netherlands Cooperative Study on the Adequacy of Dialysis, longitudinal observation of serum albumin showed a significant decrease in HD patients with the highest Kt/V compared with lower Kt/V [71] .
Calculation of the renal component of Kt/V makes assumptions about the renal handling of urea and creatinine, which are known to change with advancing age [72] . Therefore Kt/V is likely to be inaccurate in older patients.
Kt/V has been validated only in younger patients. The only RCT in HD that has shown a significant effect of Kt/V on outcome excluded elderly patients [16] . The changes in physiology that occur with age are likely to influence the relationship between Kt/V and outcome. Few studies have specifically assessed the utility of Kt/V in elderly patients. Kt/V may have little or no relevance in the elderly and, in any case, we do not know how to interpret Kt/V in the elderly.
Much of the rationale for using Kt/V, rather than symptoms and clinical signs, is to prevent uraemic complications from occurring in the future. This may require increases in dialysis dose even while the patient is asymptomatic. This strategy may have no benefit for the elderly patient with a limited life expectancy.
Clearance by HD may be limited by cardiovascular disease and access problems in elderly patients. Attempts to achieve a specified Kt/V may involve additional access interventions and more frequent or longer dialysis [73] . These will be disadvantageous to the patient and may impair quality of life. The disadvantages of attempting to achieve a predefined Kt/V are likely to outweigh the benefits.
In the elderly, quality of life will be dominated by the 'geriatric giants': immobility, cognitive impairment, abnormalities of gait and incontinence. These are unlikely to be affected by Kt/V.
Measuring the dose of dialysis or prescribing dialysis using Kt/V in elderly dialysis patients may be misleading and a distraction from assessments that are more likely to be meaningful for the patient. Good geriatric care is aimed at slowing the deterioration in physical and cognitive function and in maintaining the patient's quality of life and independence for as long as possible. Any negative effects of treatment on these aims should be taken into account.
A L T E R N A T I V E M E T R I C S O R B I O M A R K E R S FOR THE ELDERLY DIALYSIS PATIENT

Geriatric assessment
Ideally the patient should have a full geriatric assessment before starting dialysis [74] . The assessments should include objective tests of mobility and cognitive function as well as subjective assessment of quality of life, symptoms and burden of treatment. The assessments should be repeated periodically and the impact of any treatment estimated.
Dialysis time
In HD, the total diffusive time or dialysis time (td) is the duration of treatment during which clearance is applied. Modern dialysis machines automatically display elapsed td. Some of the harmful effects of HD are due to haemoconcentration and a decrease in blood volume associated with high ultrafiltration rates [75] . Shorter dialysis times require higher ultrafiltration rates. The clearance of uraemic toxin molecules, which are larger than urea, will be influenced less by blood and dialysis fluid flows compared with urea clearance. So the cleared volume for uraemic toxins will be lower during a shorter dialysis, compared with a longer dialysis even if Kt/V is the same. Some of the negative impacts of dialysis are proportional to dialysis time, including cost, inconvenience to the patient and time away from home. Patients are more likely to prefer shorter and less frequent dialysis [76] .
There is at least as much evidence for a negative association between primary outcomes (e.g. mortality, hospitalization and symptoms) and td as there is for Kt/V [77] . As with Kt/V, the evidence from RCTs that varying td can influence outcome is mixed or lacking. There is no direct evidence to support a requirement for any specific dialysis time. An RCT comparing the effects of varying td without varying Kt/V is required to prove an independent causative relationship between primary outcomes and td.
Fluid status
There is more evidence for an association between fluid status and outcome than there is for Kt/V. The significantly improved survival associated with longer dialysis has been hypothesized to be due to better control of fluid overload [78] . Fluid overload may result in symptoms and reduced cardiac function, reducing quality of life and physical function and is more likely in elderly dialysis patients [79] . Pulmonary oedema may occur in the absence of fluid overload when there is impaired left ventricular function. Dehydration may be associated with a loss of renal function and hypotension, which may be symptomatic and is a potential cause of falls, a major cause of loss of independence in the elderly. For these reasons, a comprehensive adequacy assessment should include an assessment of fluid and cardiac status. This may be particularly important in incremental dialysis, when fluid homeostasis is more critically dependent on residual renal function. Various objective measures of fluid status are available. Bioimpedance spectroscopy can quantify any over-or underhydration. Lung ultrasound can detect and quantify subclinical pulmonary oedema [80] .
Ultrafiltration rate
In HD, ultrafiltration rates >13 mL/kg/h are associated with reduced survival [81] . For this reason, it has been suggested that ultrafiltration should be limited below this rate. Other studies have not confirmed this association. It has been pointed out that limiting ultrafiltration rates to a specified limit could result in fluid overload unless dialysis time is increased or fluid accumulation between dialysis sessions is reduced.
Concentrations of key toxins
Uraemic toxicity is generally considered to be dependent on the concentrations of uraemic toxins, which depend on the generation rate as well as clearance. Generation rates are more likely to be a function of body surface area than V. It is becoming apparent that optimal Kt/V levels might be different for females and smaller patients [82] due to their differing relationship between surface area and V. This may be particularly true in the elderly, in whom V is hard to predict. Therefore it has been suggested that surface area, not V, should be used to normalize clearance in dialysis [83] .
Since the generation rates may differ in elderly patients compared with younger patients, it may be more valid to quantify dialysis adequacy from the serum levels of key uraemic toxins or surrogates rather than Kt/V. Candidate toxins might include beta-2 microglobulin, phosphate, hydrogen ion and p-cresol sulphate [84] . An individualized treatment might target specific toxins that are present in particularly high concentrations or are causing symptoms. The reduction of a specific toxin may be achieved by non-dialysis means [85] . A high level of serum phosphate, for example, might be better controlled by binders and diet rather than increasing dialysis dose. Further research is needed to link patterns of uraemic toxin levels to specific symptoms.
Self-reported outcomes
The Standardized Outcomes in Nephrology HD initiative has identified outcomes that are important to dialysis patients, their caregivers and nephrologists [86] . These include multiple self-reported outcomes. Fatigue is the first of these to be prioritized. The aim is to develop a core outcome measure (i.e. short survey) for fatigue that is validated and feasible for use in all clinical trials involving patients on HD.
C O N C L U S I O N S
According to both the pro and con arguments (Table 3) , providing dialysis with a fixed minimum Kt/V, as specified in the guidelines, is probably not appropriate for many elderly patients. Clinical guidelines are not intended to be applied rigorously in every patient. The individual needs of the patient should always take precedence.
Elderly and frail patients in particular require more individualization appropriate to their clinical condition, stage of life and priorities from their perspective. Clinical decisions should be made jointly with an informed patient or their representative.
According to the pro argument, measuring Kt/V has little or no cost, especially when automatically calculated by the dialysis machine. Although the elderly patient may not be dialyzed to a standard, predefined Kt/V level, it may be helpful to use an individualized Kt/V. Although the elderly patient would certainly benefit from a full geriatric assessment as described in the con argument, knowledge of the Kt/V could assist in achieving an individualized ideal dose for that patient and in helping to troubleshoot problems with dialysis delivery.
Incremental and palliative dialysis are options that may be of particular interest to the elderly or frail CKD patient and might deliver a relatively low Kt/V. In these patients, a trial of reduced-dose dialysis may be justified. Possible ways to reduce the dose are listed in Table 4 .
There is clearly a need for studies designed to determine the factors that influence optimal dialysis dose in elderly patients. More sophisticated measures of adequacy than Kt/V are required. Table 3 . Summary of the pro and con arguments regarding utility of Kt/V in elderly dialysis patients
C O N F L I C T O F I N T E R E S T S T A T E M E
R E F E R E N C E S
Pro Con
Kt/V is the only validated and generally accepted measure of dialysis adequacy.
Kt/V is a poor reflection of the uraemic state.
There is no evidence that target Kt/V should be different in elderly compared with younger patients.
There are physiological changes associated with ageing that are likely to influence the dialysis requirement. None of the studies on Kt/V and outcome have taken account of such issues. Elderly patients are more susceptible to malnutrition. Malnutrition is associated with and probably caused by inadequate dialysis. The nutritional consequences of inadequate dialysis may be more important in elderly patients. The UKM provides a normalized protein catabolic rate, an objective measure of nutrition, as well as Kt/V.
None of the RCTs testing increasing Kt/V has demonstrated any effect on nutrition. Elderly patients are susceptible to malnutrition even if they have normal renal function. Dialysis adequacy may have no significant additional impact on nutrition in the elderly. Subjective global assessment can be used to assess nutrition, independent of the UKM. The clinical effects of uraemia are hard to distinguish from the normal ageing process. An objective measure of dialysis adequacy such as Kt/V is required.
Quality of life in the elderly is more likely to be influenced by age and multimorbidity than by dialysis dose.
Elderly dialysis patients are particularly prone to inadequate dialysis. Objective monitoring of Kt/V is required to detect and manage this inadequacy.
Adequate dialysis is harder to achieve in the elderly and may have less influence on outcome. Monitoring Kt/V may be a distraction from more important clinical findings. Dialysis dose may be deliberately reduced in elderly patients to take into account their changing priorities. Kt/V needs to be measured to ensure that the dose remains adequate to avoid overt uraemic symptoms.
Subjective assessment of the patient's function, quality of life and the impact of dialysis may be more appropriate than any surrogate biomarker. 
